Inspiration for utilizing CSF α-synuclein came from CSF biomarkers developed for Alzheimer’s disease, including amyloid-β1–42 and total tau and phosphorylated tau. Here, MAPT is linked to early-onset autosomal dominant Alzheimer disease.